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Hilar cholangiocarcinoma, also known as Klat-
skins tumor, is a relatively rare tumor typically
aﬀecting the hepatic duct conﬂuence. Surgical treat-
ment is diﬃcult because of central location of the
tumor in the liver hilum and its intimate relationships
with adjacent liver parenchyma, the portal vein, and
hepatic arteries. During the past two decades, the
outcome of surgical treatment has improved consid-
erably, mainly owing to application of wider resec-
tions.1 Most hilar tumors, especially those with
proximal biliary extension into the segmental bile
ducts, are now resected en bloc with (extended)
hemihepatectomy including the caudate lobe and
excision of the portal vein bifurcation when in-
volved.2–10 Local inﬁltration of the tumor conﬁned to
a small, anatomically complex area only allows lim-
ited surgical exposure lest one disrupts the tumor
during surgical dissection. Surgical exploration is,
therefore, currently limited to assessment of distant
metastases and exploration of the hepatoduodenal
ligament for involvement of the hepatic arteries,
while preoperatively the approach via a left-sided or
right-sided hemihepatectomy has been determined,
with anticipation of portal vein resection when
deemed necessary on the basis of preoperative
imaging studies. Hence, whereas a more aggressive
surgical approach has increased the rate of curative
resections, the demands of diagnostic procedures and
staging systems have increased. Herein, we point out
the current issues regarding diagnosis and resect-
ability of this tumor and advocate assessment and
treatment of these patients in dedicated centers.
Benign biliary strictures, often of inﬂammatory
origin such as in primary sclerosing cholangitis, may
mimic malignant strictures at the liver hilum. There
are no imaging modalities that can reliably diﬀeren-
tiate between a benign or malignant hilar stricture.
Fine needle aspiration biopsy (FNAB) has low sen-
sitivity (approximately 30%) and should not be
encouraged because of the risk of seeding metastases.
Brush cytology obtained with ERC has limited sen-
sitivity of 50–60%, and even false positive results are
reported, especially when patients have had pro-
longed stent therapy for biliary drainage. After
longstanding pertubation, it may be difficult for the
pathologist to distinguish inflammatory cells from
tumor cells. So far, blood tumor markers are also of
limited value, the more so since plasma levels are
increased due to cholestasis, which of course is a
common feature of the tumor. Hence many of our
patients are operated on without confirmed diagno-
sis, and currently up to 15% of resected tumors are
ultimately diagnosed on histopathological examina-
tion as benign, usually inflammatory lesions.11 A
similar experience has been reported by other hepa-
tobiliary units.12,13 The difﬁculties in establishing
diagnosis preoperatively hamper the design of neo-
adjuvant therapies for this type of tumor. Cholan-
gioscopic biopsy, either by the peroral or
percutaneous route, is a diagnostic modality with
reported high sensitivity.14–16 Although its use is
presently limited because of the required endoscopic
expertise, its use is to be encouraged in the differen-
tiation between malignant and benign lesions.
Several excellent reviews dealing with diagnosis
and treatment of hilar cholangiocarcinoma have
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recently been published in the medical journals.17,18
All refer to the Bismuth-Corlette classiﬁcation in
relation with resectability of this tumor.19 Bismuth
type III tumors showing extension into the ﬁrst
segmental biliary ducts on one side of the liver re-
quire (extended) hemihepatectomy, whereas accord-
ing to these reviews, Bismuth type IV tumors, which
extend into the ﬁrst segmental ducts on both sides of
the liver, are considered unresectable. The anatomy
of the biliary ducts at the hepatic duct conﬂuence,
however, determines whether tumor-free ductal
margins can be obtained with preservation of sufﬁ-
cient remnant liver, even in Type IV tumors.7,20–22
Whereas the right anterior (B5/8) and right posterior
(B6/7) sectorial ducts usually drain into the right
hepatic duct, this duct may be short or even absent,
with both right sectoral ducts draining together with
the left hepatic duct directly into the common he-
patic duct. A hilar tumor in this situation may di-
rectly inﬁltrate into the right segmental ducts and
when also extending into the left segmental ducts
(B2/3/4) will be classiﬁed as a Bismuth type IV tu-
mor. Hilar resection in combination with a left
hemihepatectomy potentially clears all tumor. Like-
wise, on the left side, the place of drainage of the
segment 4 duct varies, and when located close to the
conﬂuence, is readily inﬁltrated by tumor. When a
tumor also extends into the right segmental ducts,
the tumor is diagnosed as a type IV tumor. When
performing extended right hemihepatectomy, seg-
ment 4 is completely removed, leaving a tumor-free
resection margin on the bile ducts of segments 2 and
3. Alternatively, the cranial part of segment 4 may
be preserved, leaving a free margin on the proximal
part of the bile duct of segment 4. Hence, it should
be emphasized among our referring colleagues that
not every Klatskin type IV tumor is by deﬁnition
unresectable and that each patient should be as-
sessed on an individual basis.
The Bismuth classiﬁcation system takes into ac-
count extension of tumor into the right and left biliary
system, with segment 4 lying anterior to the tumor.
Hilar tumors, however, equally extend in posterior
direction, involving the usually short bile ducts of the
caudate lobe (segment 1). Resection of the caudate
lobe along with all or part of segment 4, therefore, is
mandatory to remove all tumor.6,7,23 The Bismuth
classiﬁcation also does not take into account liver
parenchymal invasion, vascular invasion in portal
vein or hepatic arteries, and metastases, all crucial
criteria in the assessment of resectability of Klatskin
tumors. In addition to some form of cholangiography,
preferably noninvasively as with magnetic resonance
cholangiography (MRC), cross-sectional imaging
modalities such as computed tomography (CT) and
magnetic resonance imaging (MRI) are therefore
essential to examine these features. Most patients re-
ferred with the suspicion of hilar carcinoma already
have biliary stents placed by the referring gast-
roenterologists. Because the assessment of biliary tu-
mor is often hampered by the presence of biliary
stents, a complete work-up before considering stent
placement is therefore, advocated. Although contro-
versial in other hepato-biliary pancreatic (HPB) tu-
mors, we have continued staging laparoscopy in the
assessment of hilar cholangiocarcinoma, as a lapa-
rotomy can be avoided in 25–40% of patients, mostly
because of the detection of small peritoneal or liver
metastases.24,25
There clearly is a need for a staging system that
allows selection of surgical candidates, based on
proximal tumor extent, tumor mass, involvement of
portal vein and/or hepatic arteries, and evidence of
metastases. The TNM system is more useful for
posthoc analysis after histopathological examination
of the resection specimen.26 A preoperative staging
system has been recently proposed by the surgical
group of Memorial Sloan-Kettering Cancer Center in
New York, based on local, tumor-related factors.27
Most importantly, the decision to explore or other-
wise treat a patient with hilar cholangiocarcinoma
should be made by a multidisciplinary team consist-
ing of experienced hepatobiliary surgeons, endosco-
pists, and radiologists. It is time that the surgical
community combines efforts so that patients with this
scarce and difﬁcult tumor are assessed and treated in
specialized centers.
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